Slingshot members are tracking this event:

Agios Pharma (AGIO) to Complete Phase 1 study of AG-120 in Subjects With Advanced Solid Tumors with an IDH1 Mutation in August 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details An ongoing Phase 1 dose-escalation and expansion clinical trial evaluating AG-120 in patients with IDH1 mutant-positive advanced solid tumors, including glioma, chondrosarcoma and cholangiocarcinoma.
Additional Relevant Details
Present data from the expansion phase of the ongoing Phase 1 study of AG-120 in advanced IDH1 mutant positive low-grade glioma in the second half of 2016
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Glioma, Solid Tumor Cancer, Idh1 Inhibitor, Phase 1 Study, Ag-120, Orphan Drug, Fast Track Status, Chondrosarcoma, Carcinoma